PD-L1 as the key to survival for the advanced ovarian cancer previously treated with IDS-HIPEC.

Yong Jae Lee; Songhyeon Je; Ki Eun Seon; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim; Jung-Yun Lee

Objective: To analyze the effect of ovarian cancer related biomarkers and chemotherapy response score (CRS) on progression-free survival (PFS) and overall survival (OS) in advanced ovarian cancer patients treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: We retrospectively analyzed the medical records of 63 advanced-stage ovarian cancer patients who received NAC and underwent IDS with HIPEC at the Yonsei Cancer Center from 2015 to 2022. PFS and OS were compared in patients with and without BRCA1/2 mutation, TP53 mutation and programmed cell death-ligand 1 (PD-L1) expression. The effect of each biomarker and CRS on survival was evaluated. Results: BRCA1/2 mutations were detected in 23 (37.7%) of the 61 patients. PFS and OS were not significantly associated with BRCA1/2 mutation (p=0.522 and p=0.052, respectively). TP53 mutation was detected in 32 (80.0%) of the 40 patients. TP53 mutation was not significantly associated with either improved PFS (p=0.868) or OS (p=0.427). PD-L1 expression was detected in 4 (10.8%) of the 37 patients (immunohistochemistry cut-off value: 22C3 combined positive score, 10; 22C3 TPS, 1%; SP263, 25%). PD-L1 expression was significantly associated with longer PFS (p=0.029) but not with OS (p=0.270). Thirty-seven patients had CRS 1/2 and 19 had CRS 3. PFS was significantly improved in CRS 3 patients than CRS 1/2 patients (p=0.032). OS was not different from each CRS group (p=0.451). Conclusion: PD-L1 expression and CRS were significantly associated with longer PFS, but not with OS among patients with advanced ovarian cancer treated with IDS-HIPEC.

OVARIAN cancer; PROGRAMMED death-ligand 1; HYPERTHERMIC intraperitoneal chemotherapy; CANCER patients; OVARIES

Journal of Gynecologic Oncology, 2024, Vol 35, p30

2005-0380

Academic Journal

10.3802/jgo.2024.35.S2.P19